Anxiety disorders are the most common mental health conditions in the United States, affecting approximately 40 million adults annually — 19.1% of the population according to the National Institute of Mental Health's 2023 prevalence data. Despite being among the most treatable psychiatric conditions, only 36.9% of those affected receive any treatment, per the Anxiety and Depression Association of America.
Cognitive behavioral therapy (CBT) is the established first-line treatment for all anxiety disorders. A 2024 Cochrane review (k=69 RCTs, n=8,400) confirmed large effect sizes (Cohen's d = 0.8-1.3) compared to waitlist controls, with a number-needed-to-treat of 2-3. Dr. David Barlow, professor emeritus at Boston University's Center for Anxiety and Related Disorders, describes CBT as the single most validated psychological treatment in the history of clinical psychology.
Exposure therapy is the most effective intervention for specific phobias (response rates of 80-90% in 1-5 sessions) and is critical for OCD and PTSD. Graduated exposure allows extinction learning, where the amygdala's fear response is overwritten by new safety associations formed in the prefrontal cortex. Dr. Michelle Craske at UCLA's Anxiety and Depression Research Center has demonstrated that inhibitory learning — rather than habituation — is the primary mechanism of exposure therapy's lasting effects.
SSRIs and SNRIs are first-line pharmacological treatments. Dr. Andrea Cipriani, professor of psychiatry at the University of Oxford, led the most comprehensive network meta-analysis of anxiety medications (Lancet Psychiatry 2022, k=87 RCTs, n=25,400), finding response rates of 50-60% for sertraline, escitalopram, and venlafaxine, with onset typically at 2-4 weeks and full effect at 8-12 weeks. Benzodiazepines provide rapid relief within 30-60 minutes but carry dependence risk after 2-4 weeks of continuous use and are now recommended by the APA only for short-term crisis management, not ongoing treatment.
Combined treatment (CBT plus medication) outperforms either alone for moderate-to-severe anxiety. The landmark 2014 CALM trial (n=1,004, 18-month follow-up) published in JAMA Internal Medicine showed that collaborative care combining CBT and medication management produced 2.1 times greater improvement than usual primary care.
Exercise has the strongest evidence of any complementary intervention. Dr. Ben Singh at the University of South Australia led the 2023 umbrella meta-analysis in the British Journal of Sports Medicine (k=97 reviews, n=128,000) that found exercise reduced anxiety with a moderate-to-large effect size (Hedges' g = 0.42), comparable to first-line pharmacotherapy in mild-to-moderate cases. The effective dose: 150 minutes per week of moderate-intensity aerobic exercise, with effects detectable within 2 weeks of consistent engagement.